Suppression of rat breast cancer metastasis and reduction of primary tumour growth by the small synthetic urokinase inhibitor WX-UK1
The DOI matches its Crossref record; 1 of the 1 references it cites were found in a registry or an index.
Abstract
Summary: The serine protease uPA (urokinase-type plasminogen activator) and its receptor uPAR (CD87) are often elevated in malignant tumours, hence, inhibition of this tumour-associated plasminogen activation system provides an attractive target for therapeutic strategies. WX-UK1, a derivative of 3-aminophenylalanine in the L-conformation with inhibitory antiproteolytic properties, was tested for its specificity spectrum using specific chromogenic paranitroanilide peptide substrates. The corresponding D-enantiomer of WX-UK1 was used as a control. The anti-tumour and anti-metastatic (number of lung foci and weight of the axillary lymph nodes) properties were studied by subcutaneous administration of WX-UK1 to Brown Norwegian (BN) rats carrying orthotopically transplanted BN472 rat breast tumours. WX-UK1 selectively inhibited tumour-related proteases from rats and humans such as uPA, plasmin, or thrombin in the sub or low micromolar range. The activity was stereoselective as the D-enantiomer of WX-UK1 inhibited uPA and plas-min at approximately 70-fold higher Ki values than the active L-form. Chronical administration of the L-enantiomer of WXUK1 impaired primary tumour growth and metastasis of BN472 rat breast cancer in a dose-dependent manner. The minimum inhibitory dosage with maximal effect was between 0.15 and 0.3 mg/kg/day. The inactive D-enatiomer of WX-UK1 was not active in this respect. Daily treatment with WX-UK1 for up to 35 days was well tolerated as judged by the unchanged body and organ weight development. In conclusion, our results provide evidence that WX-UK1 as a single agent inhibits breast tumour growth and metastasis in vivo, and thus is a promising candidate drug to treat human cancer.
Overview
The claims and statistics of this paper haven’t been checked yet.
Free: it reads the open-access text and checks the first 5 claims that cite a source we can check. Create a free account to check every claim.
Integrity signals
Registry
Cites
Statistics
Verification
Claims the paper makes
The claims and statistics of this paper haven’t been checked yet.
Free: it reads the open-access text and checks the first 5 claims that cite a source we can check. Create a free account to check every claim.
Self-check
Percentages, sums and reported differences re-computed from the paper’s own numbers.
The self-check needs the paper’s full text.
Citations
Cites
Efficacy and safety of imatinib mesylate in advanced gastrointestinal stromal tumors
Demetri, G. D., von Mehren, M., Blanke, C. D., Van den Abbeele, A. D., Eisenberg, B., Roberts, P. J., Heinrich, M. C., Tuveson, D. A., Singer, S., Janicek, M., et al. (2002) · New England Journal of Medicine · doi:10.1056/nejmoa020461 · Cited by 4,389
Cited by
Weitz, J. I., Eikelboom, J. W., & Samama, M. M. (2012) · Chest · doi:10.1378/chest.11-2294 · Cited by 527
The urokinase plasminogen activator system: a target for anti-cancer therapy
Ulisse, S., Baldini, E., Sorrenti, S., & D'Armiento, M. (2009) · Current Cancer Drug Targets · doi:10.2174/156800909787314002 · Cited by 312
Weitz, J. I., Hirsh, J., & Samama, M. M. (2008) · Chest · doi:10.1378/chest.08-0673 · Cited by 262
Su, S.-C., Lin, C.-W., Yang, W.-E., Fan, W.-L., & Yang, S.-F. (2016) · Expert Opinion on Therapeutic Targets · doi:10.1517/14728222.2016.1113260 · Cited by 145
“settings.[131] Several clinical trials employing these”
Cheng, Y., Hall, T. R., Xu, X., Yung, I., Souza, D., Zheng, J., Schiele, F., Hoffmann, M., Mbow, M. L., Garnett, J. P., et al. (2022) · eBioMedicine · doi:10.1016/j.ebiom.2021.103758 · Cited by 66
Metadata
- Authors
- Setyono-Han, B., Stürzebecher, J., Schmalix, W. A., Muehlenweg, B., Sieuwerts, A. M., Timmermans, M., Magdolen, V., Schmitt, M., Klijn, J. G. M., & Foekens, J. A.
- Venue
- Thrombosis and Haemostasis
- Publisher
- Georg Thieme Verlag KG
- Published
- 2005
- Volume
- 93
- Issue
- 04
- Pages
- 779-786
- ISSN
- 0340-6245 (ISSN-L)
- 2567-689X
- OpenAlex
- W2071634551
- Cited by
- 85
- References
- 1
- FWCI
- 2.24
- Type
- journal article
- Language
- en
- Open access
- closed
About these checks
Registry, retraction, Cites and statistics results are computed, not judged, with one exception: a printed reference that no index lists is read once by a model before it counts as a citation error. Claims are extracted by a model and kept only when their quote appears verbatim in the text; each cited source is then checked, with a model’s help, for whether it says what the claim relies on. Those verdicts can be wrong — read the claim’s quote and the cited source before relying on one.
Statistics and arithmetic are recomputed, not judged.
Confidence bands are shown only for fields calibrated on our annotated test set. None is calibrated yet, so no band is shown.
What counts as a claim ›How we measure confidence ›How we check this ›
Are you an author, or do you see a problem with this page? Request a review
How to cite
Cite CoChat for the checks on this page, and the paper for its own findings.
- This page
- CoChat. (2026). Citation check: Suppression of rat breast cancer metastasis and reduction of primary tumour growth by the small synthetic urokinase inhibitor WX-UK1. https://app.cochat.ai/papers/10.1160/th04-11-0712
- The paper
- Setyono-Han, B., Stürzebecher, J., Schmalix, W. A., Muehlenweg, B., Sieuwerts, A. M., Timmermans, M., Magdolen, V., Schmitt, M., Klijn, J. G. M., & Foekens, J. A. (2005). Suppression of rat breast cancer metastasis and reduction of primary tumour growth by the small synthetic urokinase inhibitor WX-UK1. Thrombosis and Haemostasis. https://doi.org/10.1160/th04-11-0712
Data sources
Bibliographic data: Semantic Scholar, OpenAlex, Crossref.
Contains information from the Semantic Scholar Academic Graph Datasets, made available under the ODC Attribution License (ODC-BY 1.0).
Semantic Scholar’s data is described in: Kinney, R., et al. (2023). The Semantic Scholar Open Data Platform. arXiv:2301.10140.